Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

Name: Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Author: Di Bartolomeo, Maria

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. — المؤلف: Di Bartolomeo, Maria — BMC cancer 20190715

المؤلف: Di Bartolomeo, Maria
النشر: BMC cancer 20190715
الوصف: 283 p.
الموضوعات: Antibodies, Monoclonal؛ Antibodies, Monoclonal, Humanized؛ Antineoplastic Combined Chemotherapy Protocols؛ Drug Administration Schedule؛ Esophagogastric Junction؛ Female؛ Humans؛ Maintenance Chemotherapy